Drugs / BCG Tice
BCG Tice
also known as
TICE BCG · BCG · Bacille Calmette-Guerin (BCG) TICE (R) · Bacille Calmette-Guérin Tice · Bacillus Calmette-Guerin · BCG TICE strain · Tice
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06845358 | Nov 2025 → Sep 2026 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1 | NCT01868464 | May 2014 → Dec 2017 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02088892 | Mar 2014 → Jan 2015 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| — | NCT02365207 | Nov 2013 → Sep 2018 | urinary bladder cancer | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02413502 Background | May → Sep 2015 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01340820 Comparator | Dec 2010 → Feb 2012 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03091660 Comparator | Feb 2017 → Dec 2025 overdue | bladder carcinoma in situ | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00003779 Comparator | Nov 1998 → Jun 2001 | urinary bladder cancer | Swiss Cancer Institute | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG Tice | “Treatment with BCG Connaught conferred significantly greater 5-yr recurrence-free survival compared with treatment with BCG Tice (p=0.0108).” PMID 24674149 ↗ Mar 2014 |
| Known as | Bacille Calmette-Guerin (BCG) TICE (R) | “0.1 mL dose of 2x10\^6 colony-forming units (CFU) Bacille Calmette-Guerin (BCG) TICE (R) vaccine” NCT06845358 ↗ |
| Known as | Bacille Calmette-Guérin Tice | “Bacille Calmette-Guérin Tice” NCT02088892 ↗ |
| Known as | Bacillus Calmette-Guerin | “Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm.” NCT01868464 ↗ |
| Known as | BCG | “Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm.” NCT01868464 ↗ |
| Known as | BCG TICE strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06845358 ↗ |
| Known as | Tice | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003779 ↗ |
| Known as | TICE BCG | “This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it...” NCT03091660 ↗3“Patients with muscle invasive (≥T1) bladder cancer will be given 3-6 treatments (based on treatment response) intravesical TICE® BCG.” NCT02365207 ↗ “Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.” NCT01868464 ↗ “TICE BCG” NCT02413502 ↗ |
| Modality | Vaccine | “BCG vaccine” NCT02088892 ↗ |
| Route | Other | “Both arms receive BCG by catheter” NCT00003779 ↗ |